Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Turn Therapeutics Inc. (TTRX)

Turn Therapeutics posts updated investor deck; GX-03 Phase 2 readout set for Q1 2027

Neutral Impact 2 of 5 other Written later

Turn Therapeutics furnished an updated investor presentation dated October 6, 2026, as Exhibit 99.1 to a Regulation FD 8-K. The deck lays out the GX-03 pipeline, with a Phase 2 topline readout in atopic dermatitis expected in Q1 2027 and cash runway into Q3 2027, and it reports no new financial results.

Key points

  • Cash balance of $10.3 million as of June 30, 2026, with cash runway into Q3 2027
  • Stage 2 atopic dermatitis trial is currently enrolling about 135 patients; topline results expected Q1 2027
  • Phase 3 atopic dermatitis initiation planned for mid-2027; FDA Type B meeting planned for Q4 2026
  • About 29.8 million common shares outstanding as of June 30, 2026

The filing

CompanyTurn Therapeutics Inc. (TTRX)
Form8-K, current report
Filed with the SECOct 6, 2026, 7:30 PM ET
Accession number0001213900-26-107329

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.